Harmony Wellness Clinic review

Harmony names four compounding pharmacies, with cities: Strive in San Antonio, Striker in Katy, CasaPharma Rx in Stafford and Designer Drugs in Chattanooga. It prices sermorelin, NAD⁺, glutathione and PT-141 openly on the same services page, displays a LegitScript seal, publishes a Tulsa street address and names the nurse practitioner leading clinical care. Two things to read carefully: the billing periods are supplies rather than months, and no physician is named behind an APRN-led model.

Harmony Wellness Clinic, LLC is a telehealth practice based in Tulsa, Oklahoma, offering compounded semaglutide as a GLP-1-plus-B12 formulation and compounded tirzepatide as a GLP-1/GIP-plus-B12 formulation for weight loss, alongside a wellness menu that prices sermorelin, NAD⁺, glutathione, PT-141, a product called BioBoost, L-carnitine, Lipo-B and low-dose naltrexone. Clinical care is led by Kristina Stout, APRN-CNP, a certified family nurse practitioner. Appointments are delivered through its network of providers licensed across 35 states plus the District of Columbia, via the Optimantra online patient portal, with HSA, FSA and AfterPay advertised. Its homepage says no insurance is needed, while general terms say insurance may be accepted where applicable.

Portal-based telehealth with medication shipped to the door, structured around a named clinician and a published, city-by-city pharmacy roster. That roster is the reason to look here: compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, so the identity and standards of the compounder are most of what a buyer has to evaluate, and Harmony gives you four names to check rather than a category. The published state list — 35 states plus DC, enumerated — is the second real disclosure, and it lets you confirm eligibility before starting. What is not disclosed is thinner but material. No MD or DO is named behind the nurse-practitioner-led model, which is not a problem in itself but is worth knowing. The checked public pages do not establish a baseline lab protocol or its cost before a growth-hormone-axis peptide. And no coaching or lifestyle program is described beyond clinical dose management, so the offer is medication and oversight rather than a program.

Published for every peptide it sells, which is uncommon, but the billing periods vary and that is the thing to read closely. Sermorelin is $200 for a one-month supply. NAD⁺ is $200 for a five-week supply and glutathione $200 for a five-week supply — five weeks is not a calendar month, so compare the actual supply and refill schedule rather than treating $200 as a monthly charge. PT-141 is $200. BioBoost is $150 for a ten-week supply, L-carnitine $175 for twelve weeks, Lipo-B $175 for five weeks, and low-dose naltrexone $190 for a 90-day supply. On the weight-loss side, pricing scales with dose level rather than staying flat: the semaglutide formulation runs across five levels from $200 to $300 a month and the tirzepatide formulation across six levels from $250 up to $450. Before enrolling, confirm what the peptide supply actually contains in dose and quantity, whether the peptide prices escalate by level the way the GLP-1 prices do, and whether a consultation, shipping or lab fee sits outside the listed service price. General terms leave payment timing and appointment-cancellation fees open, so confirm those terms before booking.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Harmony names four 503A compounding partners with their cities, so you can research who is actually preparing your medication rather than accepting a generic assurance. That does not make a compounded product an approved one, and compounded sterile products are not FDA-reviewed for purity and potency. On the evidence, sermorelin, NAD⁺, glutathione and PT-141 are not on the same footing and the services page does not say so. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, with thin long-term human outcome data and no controlled trial behind the body-composition claims. Injected NAD⁺ has no controlled human outcome trials; oral NR and NMN are the studied forms and they raise a blood level rather than demonstrate a benefit. Injectable glutathione has essentially no controlled human outcome evidence. PT-141 is the exception and deserves to be treated as one: bremelanotide has genuine randomized human trial evidence, for hypoactive sexual desire disorder specifically, with an effect size that is real but modest — it is not a general performance or libido enhancer. Individual results vary.